...
首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients
【24h】

Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients

机译:TP53突变相关的MicroRNA的表达预测头部和颈部鳞状细胞癌患者的临床结果

获取原文
获取原文并翻译 | 示例
           

摘要

Background: TP53 mutation is associated with decreased survival rate in head and neck squamous cell carcinoma (HNSCC) patients. We set out to identify microRNAs (miRNAs) whose expression associates with TP53 mutation and survival in HNSCC. Patients and methods: We analyzed TP53 status by direct sequencing of exons 2 through 11 of a prospective series of 121 HNSCC samples and assessed its association with outcome in 109 followed-up patients. We carried out miRNA expression profiling on 121 HNSCC samples and 66 normal counterparts. miRNA associations with TP53 mutations and outcome were evaluated. Results: A TP53 mutation was present in 58% of the tumors and TP53 mutations were significantly associated with a shorter recurrence-free survival. This association was stronger in the clinical subgroup of patients subjected to adjuvant therapy after surgery. The expression of 49 miRNAs was significantly associated with TP53 status. Among these 49, we identified a group of 12 miRNAs whose expression correlates with recurrence-free survival and a group of 4 miRNAs that correlates with cancer-specific survival. The two groups share three miRNAs. Importantly, miRNAs that correlate with survival are independent prognostic factors either when considered individually or as signatures. Conclusions: miRNAs expression associates with TP53 status and with reduced survival after surgical treatment of squamous cell carcinoma of the head and neck.
机译:背景:TP53突变与头部和颈部鳞状细胞癌(HNSCC)患者的存活率降低有关。我们旨在识别其表达与HNSCC中的TP53突变和生存率相关联的MicroRNAS(miRNA)。患者和方法:通过直接测序121个HNSCC样品的前瞻性系列中的外显子2至11分析TP53状态,并评估其随访患者的109例结果。我们对121个HNSCC样品和66个正常对应物进行了miRNA表达分析。评估与TP53突变和结果的miRNA关联。结果:在58%的肿瘤中存在TP53突变,TP53突变与无复发存活率显着相关。该协会在手术后患者进行辅助治疗的患者的临床亚组中较强。 49 miRNA的表达与TP53状态显着相关。在这49中,我们确定了一组12个miRNA,其表达与无复发存活和一组与癌症特异性存活率相关的4次miRNA。两组分享了三个miRNA。重要的是,与存活相关的miRNA是单独考虑或作为签名时的独立预后因素。结论:miRNA表达与TP53状态相关联,并在头部和颈部鳞状细胞癌外科治疗后的存活率降低。

著录项

  • 来源
  • 作者单位

    Translational Oncogenomics Unit Italian National Cancer Institute 'Regina Elena' Via Elio;

    Translational Oncogenomics Unit Italian National Cancer Institute 'Regina Elena' Via Elio;

    Department of Physics of Complex Systems Weizmann Institute of Science Rehovot Israel;

    Department of Otolaryngology Rome Italy;

    Biostatistical Unit Rome Italy;

    Laboratory of Medical Physics and Expert Systems Rome Italy;

    Department of Pathology Italian National Cancer Institute 'Regina Elena' Rome Italy;

    Department of Pathology Italian National Cancer Institute 'Regina Elena' Rome Italy;

    Department of Pathology Italian National Cancer Institute 'Regina Elena' Rome Italy;

    Department of Physics of Complex Systems Weizmann Institute of Science Rehovot Israel;

    Department of Oncology Juravinski Cancer Center-McMaster University Hamilton Ontario Canada;

    Department of Oncology Juravinski Cancer Center-McMaster University Hamilton Ontario Canada;

    Department of Otolaryngology Rome Italy;

    Translational Oncogenomics Unit Italian National Cancer Institute 'Regina Elena' Via Elio;

    Translational Oncogenomics Unit Italian National Cancer Institute 'Regina Elena' Via Elio;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

    Clinical outcome; HNSCC; MicroRNA; TP53 mutation;

    机译:临床结果;HNSCC;microRNA;TP53突变;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号